Moleculin Biotech (MBRX) Given Media Impact Score of 0.02
Media headlines about Moleculin Biotech (NASDAQ:MBRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Moleculin Biotech earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.2130676856326 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, ValuEngine upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Shares of Moleculin Biotech (MBRX) traded down 2.25% during midday trading on Wednesday, reaching $2.61. The company had a trading volume of 202,113 shares. Moleculin Biotech has a one year low of $0.71 and a one year high of $6.84. The company’s market capitalization is $52.88 million. The company has a 50 day moving average of $2.52 and a 200 day moving average of $1.45.
Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. Analysts predict that Moleculin Biotech will post ($0.34) EPS for the current fiscal year.
In other Moleculin Biotech news, major shareholder Waldemar Priebe sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.70, for a total transaction of $170,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.80% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Receive News & Stock Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related stocks with our FREE daily email newsletter.